EUVIMEDEUVIMED entdecken
Open Access

Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults

Jessica Stiefel iD, Brian H Kushner iD, Stephen S Roberts iD, Fiorella Iglesias-Cardenas iD, Kim Kramer, Shakeel Modak iD

JCO Precision Oncology · 2023

DOI: 10.1200/po.23.00138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Jessica Stiefel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neuroblastoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Adult-onset neuroblastoma (AON) differs significantly in biology and clinical behavior from childhood-onset disease. AON poses therapeutic challenges since tolerance of intensive multimodality therapies that are standard of care for pediatric neuroblastoma (NB) is poor. AON is enriched for somatic mutations including anaplastic lymphoma kinase ( ALK), deemed to be an oncogenic driver in NB. ALK inhibitors (ALKis), therefore, have the potential to be of therapeutic benefit. The purpose of this study is to report on their use in AON. METHODS A single-center retrospective review of adults with NB receiving ALKi (2012-2022) was performed. Response was evaluated using International Neuroblastoma Response Criteria. RESULTS Fifteen patients with ALK-mutated AON were treated with US Food and Drug Administration–approved ALKi starting at a median age of 34 (16-71) years. Initial ALKi was lorlatinib, crizotinib, and alectinib in seven, five, and three patients respectively; seven received multiple ALKis due to progressive disease/intolerability of one agent. All patients experienced ≥grade 2 adverse events (AEs): crizotinib and alectinib were associated primarily with gastrointestinal AEs, lorlatinib with neurologic AEs, weight gain, and hyperlipidemia resulting in dose reduction or discontinuation of ALKi in several patients. No responses were observed with crizotinib (n = 5 patients), ceritinib, alectinib, or brigatinib (n = 1 each). Of the 13 patients receiving lorlatinib, four, five, and four patients had a complete or partial response (major response rate 69%), and stable disease, respectively. Responses were noted in all disease compartments; complete metabolic response was seen in two L2 patients. Ten of 13 patients remain progression-free at a median of 19 (6-50) months on lorlatinib. Three (two receiving dose-reduced therapy) had progressive disease. Median survival from start of first ALKi was 43 ± 26 months. CONCLUSION ALKis, particularly lorlatinib, are effective treatment options for AON. However, AEs necessitating dose reduction are common.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeuroblastomaAdultAgedHumansMiddle AgedAnaplastic Lymphoma KinaseCrizotinibLactams, MacrocyclicProtein Kinase InhibitorsAdolescentYoung AdultAminopyridinesLactamsPyrazoles

Substanzen

Anaplastic Lymphoma KinaseCrizotinibLactams, MacrocyclicProtein Kinase InhibitorslorlatinibAminopyridinesLactamsPyrazolesALK protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Jessica Stiefel, Brian H Kushner, Stephen S Roberts, Fiorella Iglesias-Cardenas, Shakeel Modak

Förderung

  • NCI NIH HHS

Zitieren

APA

Stiefel, J., Kushner, B. H., Roberts, S. S., Iglesias-Cardenas, F., Kramer, K., & Modak, S. (2023). Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults. JCO Precision Oncology. https://doi.org/10.1200/po.23.00138

Vancouver

Stiefel J, Kushner BH, Roberts SS, Iglesias-Cardenas F, Kramer K, Modak S. Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults. JCO Precision Oncology. 2023. doi:10.1200/po.23.00138

BibTeX
@article{Stiefel2023,
  author = {Stiefel, Jessica and Kushner, Brian H and Roberts, Stephen S and Iglesias-Cardenas, Fiorella and Kramer, Kim and Modak, Shakeel},
  title = {Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.23.00138}
}
Kostenlos starten →